Phase 2 Bipolar Disorder Trial, Recruiting NCT07220460 Sponsor: AbbVie Condition: Bipolar Disorder
Back to Bipolar Disorder

Phase 2 Bipolar Disorder Trial, Recruiting

NCT07220460
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Your Body Mass Index (BMI) — a measure of body weight relative to height — must be between 18.0 and 40.0.
  • You must have been diagnosed with bipolar I or II disorder (without psychotic features) according to standard psychiatric guidelines, and currently be going through a depressive episode that has lasted at least 4 weeks but no longer than 12 months.
  • Your physical exam, blood/lab tests, vital signs, and heart tracing (ECG) results must be normal, or any unusual results must be considered not medically significant by the study doctor.
  • You must have no history of a psychiatric hospital stay (including intensive outpatient programs) in the past 3 months.
  • You must have no history of schizophrenia, other psychotic disorders, dissociative disorders, or memory/cognitive disorders at any point in your life.
  • You must have no history of moderate or severe drug or alcohol misuse (other than nicotine) in the past 6 months.
  • If you have other stable mental health conditions (such as PTSD or OCD), you may still qualify, as long as those conditions have not required any medication that is not allowed in this trial within the past 12 months.

Who may not be able to join:

  • People whose manic symptoms score above 12 on a standard rating scale (called the Young Mania Rating Scale) at the start of the study.
  • People who have had an allergic reaction or strong sensitivity to the study drug or similar medications.
  • People with a serious or unstable physical health condition that could affect the study or put them at risk — this includes certain heart, kidney, liver, lung, blood, hormonal, digestive, or neurological conditions, or a history of most types of cancer (confirm with trial site if your condition has been stable for over a year, as exceptions may apply).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: ABBVIE INC., AbbVie

Phone: 844-663-3742

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Registry
ClinicalTrials.gov
Start date
30 September 2025
Est. completion
1 April 2027

Where this trial is recruiting

Puerto Rico 🇺🇸 United States

Primary endpoints

Number of Participants Experiencing Adverse Events; Number of Participants with Abnormal Change From Baseline in Vital Sign Measurements; Number of Participants with Change from Baseline in Electrocardiogram (ECG); Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be Assessed; Change From Baseline in Simpson-Angus Scale (SAS); Change From Baseline in Abnormal Involuntary Movement Scale (AIMS); Change From Baseline in Barnes Akathisia Rating Scale (BARS); Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS); Change From Basel...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov